Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BioGend Therapeutics Co., Ltd. (6733) Financial Statements

BioGend Therapeutics Co., Ltd. Financial Overview

BioGend Therapeutics Co., Ltd.'s market cap is currently NT$2.80B. The company's EPS TTM is NT$-0.54; its P/E ratio is -38.91; BioGend Therapeutics Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total RevenueNT$ 222.34MNT$ 167.65MNT$ 109.91MNT$ 31.45MNT$ 9.27M
Gross ProfitNT$ 160.16MNT$ 130.51MNT$ 89.62MNT$ 22.78MNT$ 3.06M
Operating IncomeNT$ -110.50MNT$ -122.26MNT$ -176.54MNT$ -213.80MNT$ -144.25M
EBITDANT$ -60.73MNT$ -74.38MNT$ -113.94MNT$ -160.62MNT$ -104.71M
Net IncomeNT$ -84.61MNT$ -116.47MNT$ -156.32MNT$ -184.46MNT$ -138.49M
Balance Sheet
Cash & Short-Term InvestmentsNT$ 517.90MNT$ 619.02MNT$ 724.27MNT$ 493.40MNT$ 689.28M
Total AssetsNT$ 815.38MNT$ 912.70MNT$ 1.05BNT$ 821.82MNT$ 1.02B
Total DebtNT$ 6.58MNT$ 9.43MNT$ 13.09MNT$ 15.77MNT$ 4.42M
Net DebtNT$ -211.33MNT$ -209.59MNT$ -317.42MNT$ -147.88MNT$ -131.90M
Total LiabilitiesNT$ 57.74MNT$ 66.19MNT$ 93.71MNT$ 90.56MNT$ 80.42M
Stockholders' EquityNT$ 742.09MNT$ 817.67MNT$ 940.96MNT$ 702.86MNT$ 887.54M
Cash Flow
Free Cash FlowNT$ -65.52MNT$ -99.56MNT$ -164.76MNT$ -186.96MNT$ -137.47M
Operating Cash FlowNT$ -63.66MNT$ -98.91MNT$ -138.72MNT$ -168.78MNT$ -136.80M
Investing Cash FlowNT$ 66.43MNT$ -8.20MNT$ -89.64MNT$ 201.70MNT$ -134.27M
Financing Cash FlowNT$ -3.70MNT$ -3.64MNT$ 396.42MNT$ -4.81MNT$ 287.85M

Currency in TWD

BioGend Therapeutics Co., Ltd. Earnings and Revenue History

-250M0250M500M-12000 %-8000 %-4000 %0 %EarningsProfit Margin2019202020212022202320242025RevenueEarningsProfit Margin
Income Statement >

BioGend Therapeutics Co., Ltd. Liabilities to Assets

0400M800M1.2B0 %4 %8 %12 %LiabilitiesLiabilities to Assets2019202020212022202320242025AssetsLiabilitiesLiabilities to Assets
Balance Sheet >

BioGend Therapeutics Co., Ltd. Cash Flow

-400M-200M0200M400M600M2019202020212022202320242025OperatingInvestingFinancing
Cash Flow >

BioGend Therapeutics Co., Ltd. Forecast EPS vs Actual EPS

-0.2-0.2-0.1-0.100Q2 25Q3 25Q4 25Q1 26Q3 26Q4 26EPS EstimateBeatMiss
Earnings >